Specialty Pharma Pipeline News

The future of specialty medications, according to Tharaldson, will be defined by increased competition and a variety of high-impact indications. 2/ The biggest competition factor will be biosimilar approvals Through 2022, there will be a $54.4 billion potential for biosimilars as 71 specialty drug p...

Full description

Saved in:
Bibliographic Details
Published in:Managed Healthcare Executive 2018-12, Vol.28 (12), p.46-46
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Biological products
Cancer therapies
Drugs
Oncology
Pharmaceuticals
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The future of specialty medications, according to Tharaldson, will be defined by increased competition and a variety of high-impact indications. 2/ The biggest competition factor will be biosimilar approvals Through 2022, there will be a $54.4 billion potential for biosimilars as 71 specialty drug patents will expire, Tharaldson said. Biosimilars face a variety of legal hurdles and will also struggle to gain market share. 3/ The top two pipeline categories are cancer and orphan drugs Tharaldson also covered several important categories that will be largely influenced by specialty medications in the coming years. According to Tharaldson, 30% of new orphan drugs will be blockbuster drugs. 4/ NASH could see major drug developments in 2019 One other notable treatment class is for nonalcoholic steatohepatitis (NASH).
ISSN:1533-9300
2150-7120